Proactive Investors - Run By Investors For Investors

ImmunoPrecise boosts screening capability with lab equipment purchase

A second Intellicyt iQue Screener PLUS device allows scientists to reduce lead discovery time while conserving samples and reducing reagent cost
An illustration of antibodies
The equipment upgrade advances ImmunoPrecise's strategic vision, according to the company

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA) said Tuesday that it has acquired additional integrated laboratory equipment for high-throughput antibody screening.

The Victoria, British Columbia, biotech company said in a statement that its purchase of a second Intellicyt iQue Screener PLUS allows its scientists to reduce lead discovery time while conserving samples and reducing reagent cost.

READ: Immunoprecise Antibodies reports 2Q revenue doubled on increased capacity, European expansion

Other antibody screeners, according to the company, report on binding one target at a time, which makes the discovery process time-consuming and can require large amounts of target protein.

"The decision to acquire a second Intellicyt iQue will further support IPA's strategic vision of continued growth and expansion in providing end-to-end therapeutic antibody discovery services to a rapidly expanding list of pharma and biotech clients," said CEO Jennifer Bath in a statement.

The company operates globally to offer antibody services from target analysis to pre-clinical studies. It works out of labs in Victoria as well as in Utrecht and Oss in the Netherlands.

Shares traded at C$0.68 in Monday’s Canadian trading. They were down US$0.04 to US$0.51 on the OTC Markets.

Contact Dennis Fitzgerald at [email protected]

View full IPA profile View Profile

Immunoprecise Antibodies Ltd Timeline

Related Articles

bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use